Torben Danger
Managing Director and Senior Partner; Global Leader, Health Care Practice
New York
Medical Devices & Technology
Torben Danger on the Evolving MedTech Market
Torben Danger is the global leader for Boston Consulting Group's Health Care practice, which encompasses biopharma, medical technologies, payers, providers, health systems, and global health.
Since joining BCG in 2005, Torben has centered his client work on strategy, sales and marketing, integration, transformation, and operations projects in the medical technology and biopharma industries.
Through his assignments across many health care segments and locations, Torben has developed a firsthand appreciation of how cost pressure, provider consolidation, and other trends such as digitization affect the industry.
AREAS OF EXPERTISE
EDUCATION
- PhD, law, University of Freiburg
- MA, law, University of Freiburg
Publications and Videos
Takeda’s Partnerships
Chief Data and Technology Officer Gabriela Richie on the biopharma company’s approach to partnerships
Takeda’s Chief Data and Technology Officer on Leadership
Gabriela Richie’s thoughts on the three key aspects of leadership in today’s volatile environment.
How Takeda Set Up Operations to Accelerate Digital Transformation
Chief Data and Technology Officer Gabriela Richie on setting up the organization to deliver value with minimal investment
Takeda’s Transformation Success Factors
Chief Data and Technology Officer Gabriela Richie on the biopharma company’s winning approach to digitalization
Biogen’s CFO on Leading a People-First Transformation
Mike McDonnell explains how the global biotech is charting new paths to patientsvia Fit for Growth, its corporate transformation initiative.
The Three Responsibilities of Management
Biogen CFO Mike McDonnell on the leadership lessons he learned from his roles across different industries.
CEO Paul Hudson on Sanofi’s Bold New Strategy and “Snackable AI”
AI is playing a role in facilitating innovation in drug discovery and development at one of the world’s largest biopharmaceutical companies.
Three Indispensable Leadership Lessons
FNIH CEO Julie Geberding explains what she's learned from her experience in academia, industry, and the public sector.
Building Breakthroughs in Gene Therapy Development
The Bespoke Gene Therapy Consortium, a public-private partnership led by the FNIH, has produced a protocol for streamlining development time significantly.